PAH (phenylalanine hydroxylase; HGNC:8582, NCBI Gene 5053) is the gene on chromosome 12q23.2 encoding phenylalanine hydroxylase — the liver enzyme that hydroxylates phenylalanine to tyrosine (with tetrahydrobiopterin as cofactor): the phenylketonuria (PKU) gene, whose recessive loss causes the classic inborn error of metabolism that newborn screening was invented to catch.
Approved Symbol
PAH (HGNC:8582)
Chromosomal Locus
12q23.2
Encoded Product
PAH — a 52-kDa tetrameric iron enzyme (452 aa/monomer)
Genomic organization: 13 exons; the catalytic iron domain and the C-terminal tetramerization arm — more than 1,000 pathogenic variants known (missense the majority), with genotype loosely predicting severity.
Expression: Liver (and kidney) — the phenylalanine-catabolism organ; the enzyme's BH4 cofactor recycled by dihydropteridine reductase, the separate BH4-deficiency PKU mimics the differential diagnosis.
Screening history:
Screening history: The Guthrie bacterial-inhibition assay (1963) the first population newborn screen; PKU's early-treated normal-outcome generation the proof that newborn screening works — the program every modern expansion cites.
Maternal PKU: The treated PKU mother's phenylalanine crossing the placenta — maternal hyperphenylalaninemia's teratogenicity (microcephaly, cardiac defects) requiring preconception diet control; the adult-PKU management file that pegvaliase also serves.
The catabolic gate: PAH's hydroxylation the sole route clearing dietary phenylalanine to tyrosine — loss accumulating phenylalanine (neurotoxic in development) while tyrosine becomes conditionally essential; the metabolic logic behind the phenylalanine-restricted diet, phenylalanine.
Genotype spectrum: Null variants the severe classic PKU; missense variants spanning mild hyperphenylalaninemia; some variants BH4-responsive (sapropterin the pharmacological chaperone restoring activity — precision therapy from genotype).
Clinical & Therapeutic Significance
PKU: Autosomal recessive; untreated severe variants causing intellectual disability — newborn screening (the Guthrie card) and the phenylalanine-restricted diet preventing it; the first population-screening program in metabolic medicine.
Therapeutics: Sapropterin (BH4) for responsive genotypes; pegvaliase (PEGylated phenylalanine ammonia-lyase) degrading phenylalanine for adults — the enzyme-substitution route; large-neutral-amino-acid supplements the adjunct.